Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent.
A new class of marine compounds, the didemnins, with potent antitumor activity has been identified. They share the novel structure of a cyclic depsipeptide. Among three structurally related compounds, didemnin B is by far the most potent in its in vitro cytotoxicity and in vivo antitumor activity (0.001 microgram/ml inhibits the growth of L1210 leukemia cells by 50%). It also demonstrates good antitumor activity against B16 melanoma and moderate activity against M5076 sarcoma and P388 leukemia. The compound also has good antiviral and potent immunosuppressive properties. Although the precise mechanism of action for the cytotoxicity remains unknown, the agent inhibits protein synthesis more than DNA synthesis and the inhibition of protein synthesis is closely correlated with inhibition of L1210 cell growth. Toxicology studies in CD2F1 mice, Fischer 344 rats and beagle dogs reveal that major target organs are the lymphatics, gastrointestinal tract, liver and kidney. Phase I trials are currently in progress under the auspices of the National Cancer Institute.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity; D000998:Antiviral Agents / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D047630:Depsipeptides; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010456:Peptides, Cyclic / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D014410:Tumor Stem Cell Assay
D000903:Antibiotics, Antineoplastic; D000998:Antiviral Agents; D047630:Depsipeptides; D007166:Immunosuppressive Agents; D010456:Peptides, Cyclic; C030051:didemnins